Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has been effective diligently but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set out what follows prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire interview that I came away with a poor opinion of the company.

Irony of irony, the poor opinion of mine of the company has grown steadily, although the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the know-how and also associated intellectual property from Progenics to CytoDyn, and also roughly 25 million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) along with the first brand new drug program approval ($five million), and even royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and numerous indications, it has this individual treatments in addition to a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations in addition to multiple publications.

Might all this be smoke and mirrors? That’s a question I have been asking myself from the really start of my interest in this company. Judging by way of the multiples of thousands of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or possibly some might say cult stock. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *